Female carriers of pathogenic variants in BRCA1 or BRCA2—both high-penetrance genes associated with hereditary breast and ovarian cancer (HBOC)—face a lifetime risk of 50%‐80% for breast cancer, a 60% risk for contralateral breast cancer, and up to 40% for ovarian cancer [1, 4, 5]. This evidence concerns the gene BRCA1 and breast carcinoma.